|
 NRP290, our second
most advanced compound, is a conditionally bioreversible derivative
(CBD) of hydrocodone, an opioid widely used in combination
with other non-opioid analgesics to treat acute pain. Acute
pain usually lasts for a short time, typically not more than
a month. Treatment for acute pain may consist of non-opioid
analgesics and non-steroidal anti-inflammatory drugs. In more
severe cases of acute pain, opioids, such as Lortab®,
Vicodin® and Vicoprofen® and Demerol®, are commonly
prescribed. While opioids are the most effective drugs available
for treating pain, there is increasing concern with respect
to their potential for abuse and propensity for addiction.
Repeated administration of opioids, including hydrocodone,
can create psychological addiction as well as increased tolerance
resulting in the potential for overdose. Overdose can result
in respiratory depression, coma, hypotension, cardiac arrest
and death.
On June 28, 2005, we filed an Investigational New Drug application
with the FDA. On September 12, 2005, we presented the results
of our first clinical trial on NRP290. Further clinical development
is ongoing.
|
